Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (5454)	5/11/2009 10:30:27 AM
From: RockyBalboa	Respond to of 6370

gg that´s amazing. I`ll have to check yahoo boards for a good laugh.

To: Kevin Podsiadlik who wrote (5454)	5/11/2009 10:44:08 AM
From: RockyBalboa	Read Replies (2) \| Respond to of 6370

Lots of sweeteners in this offering: Hemispherx Biopharma Announces $18.3 Million Public Equity Offerings PHILADELPHIA, May 11, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (AMEX:HEB) announced today that it has agreed to sell up to $18.3 million in common stock and warrants in a registered offering to two institutional investors. The investors will purchase today, for $15 million cash, common shares of its stock at $1.10 per share. Investors will also receive ies A warrants to purchase 6,136,364 shares of Hemispherx Biopharma, Inc.'s common stock. The Series I warrants have an exercise price of $1.65 per share ad are exercisable at any time after the six-month anniversary of the closing of the transaction and before the fifth anniversary of such initial exercise date. The investors also received 3,000,000 Series II warrants that are exercisable at $1.10 and have a 45 day term. The closing of the offering is expected to take place on or about May 16, 2009, subject to the satisfaction of customary closing conditions, including the approval of an application for the listing of additional shares by the NYSE Amex exchange. Hemispherx Biopharma, Inc. plans to use the net proceeds from the offering to fund commercialization of Alferon N and for other research and development and general corporate purposes.

To: Kevin Podsiadlik who wrote (5454)	5/11/2009 11:00:22 AM
From: RockyBalboa	Respond to of 6370

The HEB CFS cure applied to some folks, can´t say it is not effective: messages.finance.yahoo.com messages.finance.yahoo.com Snatch & Stomp balls... messages.finance.yahoo.com

To: Kevin Podsiadlik who wrote (5454)	7/30/2009 3:32:22 PM
From: RockyBalboa	Respond to of 6370

Wasting no time: Perhaps the lemon for the most questionable pump goes to INO. Yesterday it run 350% on a really dubious PR (and intraday from $2 to $3.50), and then announced a 30MM offering. Today it lost 50% from the peak, after RR announced its proven "direct offering" which we know from HEB and others. The yahoo board is boiling over.. (while the sheriffs at the nasd are looking the other way).

To: Kevin Podsiadlik who wrote (5454)	7/30/2009 5:15:12 PM
From: RockyBalboa	Respond to of 6370

Today I mused about RR being pretty busy doing smallcap deals. Earnings for RR out: BRIEF-Rodman and Renshaw Capital Q2 results July 30 (Reuters) - Rodman & Renshaw : * Announces financial results for the second quarter of 2009 * Q2 earnings per share $0.42 * Q2 revenue $33.4 million * Says investment banking revenue was $27.0 million for the second quarter ((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) ((For more news, please click here [RODM.O]))